16-1-3-3　ⓔ文献

  1. Seino Y, Yabe D: Glucose–dependent insulinotropic polypeptide and glucagon–like peptide–1: Incretin actions beyond the pancreas. J Diabetes Investig, 2013; 4: 108–130.

  2. Turton MD, O’Shea D, et al: A role for glucagon–like peptide–1 in the central regulation of feeding. Nature, 1996; 379: 69–72.

  3. Nauck MA, Niedereichholz U, et al: Glucagon–like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol, 1997; 273: E981–988.

  4. Yamada C, Yamada Y, et al: Genetic inactivation of GIP signaling reverses aging–associated insulin resistance through body composition changes. Biochem Biophys Res Commun, 2007; 364: 175–180.

  5. Miyawaki K, Yamada Y, et al: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med, 2002; 8: 738–742.

  6. Narita T, Katsuura Y, et al: Miglitol induces prolonged and enhanced glucagon–like peptide–1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med, 2009; 26: 187–188.

  7. Maeda H, Kubota A, et al: Long–term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET–K1) to a target of HbA1c ＜7％．J Endocrinol Invest, 2013; 36: 568–573.

  8. Seino Y, Rasmussen MF, et al: Efficacy and safety of the once–daily human GLP–1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin, 2010; 26: 1013–1022.

  9. Tajiri, Y, Tsuruta M, et al: Long–term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocr J, 2012; 59: 197–204.

  10. Mikada A, Narita T, et al: Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over–weight Japanese patients with type 2 diabetes. “The MASTER randomized, controlled trial”．Diabetes Res Clin Pract, 2014; 106: 538–547.